Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

@article{Yale2014EfficacyAS,
  title={Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.},
  author={Jin Yale and George C Bakris and Bertrand Cariou and Jos{\'e} Manuel Bravo Nieto and Elias David-Neto and Dennis Yue and Ewa Alina Wajs and Katherine W. Figueroa and Joel Jiang and Gordon T. Law and Keith Usiskin and Gary E. Meininger},
  journal={Diabetes, obesity & metabolism},
  year={2014},
  volume={16 10},
  pages={
          1016-27
        }
}
AIM This study evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and within a subset of Stage 3 chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] ≥ 30 and <50 ml/min/1.73 m(2)). METHODS In this 52-week, randomized, double-blind, placebo-controlled study, patients (N = 269; mean eGFR, 39.4 ml/min/1.73 m(2)) received canagliflozin 100 or 300 mg and placebo once daily. Efficacy… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 61 CITATIONS

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 13 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Similar Papers

Loading similar papers…